Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review

References

• Epilepsy Foundation. Facts about seizures and epilepsy. 2019; [cited 2020 Jan 23]. Available from: https://www.epilepsy.com/learn/about-epilepsy-basics/facts-about-seizures-and-epilepsy.
   Google Scholar
• World Health Organization. Epilepsy: a public health imperative. 2019; [cited 2020 Jan 20]. Available from: https://www.who.int/mental_health/neurology/epilepsy/report_2019/en/.
   Google Scholar
• Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):522–530. .
   PubMed Web of Science ®Google Scholar
• Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc. 1996;71(6):576–586.
   PubMed Web of Science ®Google Scholar
• Perucca P, Scheffer IE, Kiley M. The management of epilepsy in children and adults. Med J Aust. 2018;208(5):226–233.
   PubMed Web of Science ®Google Scholar
• Golyala A, Kwan P. Drug development for refractory epilepsy: the past 25 years and beyond. Seizure. 2017;44:147–156.
   PubMed Web of Science ®Google Scholar
• Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6(9):793–804.
   PubMed Web of Science ®Google Scholar
• Alsfouk BA, Alsfouk AA, Chen Z, et al. Pharmacological outcomes in teenagers with newly diagnosed epilepsy: a 30-year cohort study. Epilepsia. 2019;60(6):1083–1090.
   PubMed Web of Science ®Google Scholar
• Chen Z, Brodie MJ, Liew D, et al., Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study. JAMA Neurol. 75(3): 279–286. 2018.
   PubMed Web of Science ®Google Scholar
• Tian N, Boring M, Kobau R, et al. Active epilepsy and seizure control in adults - United States, 2013 and 2015. MMWR Morb Mortal Wkly Rep. 2018;67(15):437–442.
   PubMed Web of Science ®Google Scholar
• Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70.
   PubMed Web of Science ®Google Scholar
• XCOPRI® (cenobamate tablets), for oral use, CV [prescribing information]. Paramus, NJ: SK Life Science, Inc.; 2020 August.
   Google Scholar
• Strzelczyk A, Mann C, Willems LM, et al. Cenobamate for the treatment of focal epilepsies. Expert Opin Pharmacother. 2020:1–9. https://doi.org/10.1080/14656566.2020.1803830
   Google Scholar
• Buckley CT, Waters OR, DeMaagd G. Cenobamate: a new adjunctive agent for drug-resistant focal onset epilepsy. Ann Pharmacother. 2020 Jul 6;1060028020941113. DOI:https://doi.org/10.1177/1060028020941113. Online ahead of print.
   Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111:85–141.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Cho JH, Shin H, et al. Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175–182.
   PubMed Web of Science ®Google Scholar
• Sharma R, Nakamura M, Neupane C, et al. Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879:173117.
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013;103(1):2–30. .
   PubMed Web of Science ®Google Scholar
• Melnick S, Shin H, Roucard C, et al. Cenobamate (YKP3089) dose-dependently reduced spike-and-wave discharges in the genetic absence epilepsy rats from strasbourg (GAERS) animal model [poster]. Society for Neuroscience Annual Meeting, October 19–23, Chicago, IL; 2019.
   Google Scholar
• Vernillet L, Greene SA, Kamin M. Pharmacokinetics of cenobamate: results from single and multiple oral ascending-dose studies in healthy subjects. Clin Pharmacol Drug Dev. 2020;9(4):428–443.
   PubMed Web of Science ®Google Scholar
• Vernillet L, Greene SA, Kim HW, et al. Mass balance, metabolism, and excretion of cenobamate, a new antiepileptic drug, after a single oral administration in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2020;45(4):513–522.
   PubMed Web of Science ®Google Scholar
• Greene S, Kwak C, Kamin M, et al. The effect of cenobamate on the single dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects [poster]. American Society for Clinical Pharmacology & Therapeutics Annual Meeting, March 13–16, 2019, Washington, DC.
   Google Scholar
• Vernillet L, Kamin M Drug–drug interactions between cenobamate and other antiepileptic drugs: results from phase I studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium [poster]. American Society for Clinical Pharmacology & Therapeutics Annual Meeting, March 21–24, 2018, Orlando, FL.
   Google Scholar
• Greene SA, Vernillet L A review of the pharmacokinetic properties of cenobamate (YKP3089), a novel antiepileptic drug for the treatment of uncontrolled focal seizures [poster]. American Epilepsy Society Annual Meeting, December 6–10, 2019, Baltimore, MD.
   Google Scholar
• Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology. 2004;63(10 suppl 4):S40–S48.
   PubMed Web of Science ®Google Scholar
• Jacob L, Bohlken J, Schmitz B, et al. Incidence of epilepsy and associated factors in elderly patients in Germany. Epilepsy Behav. 2018;90:107–111.
   PubMed Web of Science ®Google Scholar
• Motika PV, Spencer DC. Treatment of epilepsy in the elderly. Curr Neurol Neurosci Rep. 2016;16(11). https://doi.org/10.1007/s11910-016-0696-8.
   Google Scholar
• Doose H, Waltz S. Photosensitivity–genetics and clinical significance. Neuropediatrics. 1993;24(5):249–255.
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenite DGA, Diventura BD, Pollard JR, et al. Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089). Neurology. 2019;93(6):E559–E567. .
   PubMed Web of Science ®Google Scholar
• Chung SS, French JA, Kowalski J, et al., Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 94(22): e2311–e2322. 2020.
   PubMed Web of Science ®Google Scholar
• Krauss GL, Klein P, Brandt C, et al., Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 19(1): 38–48. 2020.
   PubMed Web of Science ®Google Scholar
• Sperling MR, Klein P, Aboumatar S, et al., Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 61(6): 1099–1108. 2020.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Mameniskiene R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87(3):314–323.
   PubMed Web of Science ®Google Scholar
• French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589–596.
   PubMed Web of Science ®Google Scholar
• Arnold S. Cenobamate: new hope for treatment-resistant epilepsy. Lancet Neurol. 2020;19(1):23–24.
   PubMed Web of Science ®Google Scholar
• French JA. Cenobamate for focal seizures - a game changer? Nat Rev Neurol. 2020;16(3):133–134.
   PubMed Web of Science ®Google Scholar
• Slater J, Chung S, Huynh L, et al. Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: meta-analysis of pivotal trials. Epilepsy Res. 2018;143:120–129.
   PubMed Web of Science ®Google Scholar
• French JA, Chung SS, Krauss GL, et al. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study [poster]. American Epilepsy Society Annual Meeting, December 6–10, 2019, Baltimore, MD.
   Google Scholar
• Klein P, Krauss GL, Aboumatar S, et al. Long-term efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study [poster]. American Epilepsy Society Annual Meeting, December 6–10, 2019, Baltimore, MD.
   Google Scholar
• Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–1244.
   PubMed Web of Science ®Google Scholar
• The North American antiepileptic drug pregnancy registry. 2020; [cited 2020 Jun 25]. Available from: http://www.aedpregnancyregistry.org/.
   Google Scholar
• Josephson CB, Patten SB, Bulloch A, et al. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58(5):764–771.
   PubMed Web of Science ®Google Scholar
• LAMICTAL (lamotrigine) tablets, for oral use. LAMICTAL (lamotrigine) chewable dispersible tablets, for oral use. LAMICTAL ODT (lamotrigine) orally disintegrating tablets, for oral use [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2019 August.
   Google Scholar
• Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs–best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia. 2008;49(7):1239–1276.
   PubMed Web of Science ®Google Scholar